There is currently no strong evidence that additional immune therapy benefits patients with renal cell carcinoma who were ...

Researchers have identified type 5 collagen as a key factor in kidney fibrosis, revealing its potential as a biomarker to predict chronic kidney disease progression. A repurposed anti-cancer drug, ...

New UCLA research conducted using mouse models and human genetic data has uncovered a critical factor that determines how much scarring occurs following kidney injury, leading scientists to identify a ...

New UCLA research conducted using mouse models and human genetic data has uncovered a critical factor that determines how much scarring occurs following kidney injury, leading scientists to identify a ...

However, a new Food and Drug Administration (FDA ... and giving many more men the chance to access this innovative therapy. Trial data showed using Pluvicto in this setting reduced the risk ...

The trial will begin with a dose-escalation phase to determine the appropriate maintenance therapy dosage, followed by an optional expansion phase. Dr. Myriam Mendila, CureVac’s Chief Scientific ...

Lisa Rinna and Harry Hamlin revealed one of the secrets to their long-lasting marriage: hormone replacement therapy. Rinna, 61, broached the topic during the Friday, April 4, episode of her and ...

IDE196 has been granted Breakthrough Therapy designation for neoadjuvant treatment of primary uveal melanoma, highlighting its potential in addressing unmet medical needs. The FDA's Breakthrough ...

Professor Kenji Osafune (Department of Cell Growth and Differentiation) and his team of researchers have devised an effective means to grow iPS cell-derived kidney progenitor cells, paving the way for ...

has cleared the company’s Investigational New Drug (IND) application for EPI-321, a first-in-class epigenetic therapy for the treatment of facioscapulohumeral muscular dystrophy (FSHD), a genetic ...

today announced that the U.S. Food and Drug Administration (FDA) has granted Fast Track designation to BIIB080, an investigational antisense oligonucleotide (ASO) therapy targeting tau, for the ...

That same year, the FDA cleared the U.S.’ first gene therapy, Roche’s Luxturna ... whether those efforts will continue under Marks’ replacement—or face major disruptions—remains an ...